Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating pumitamig BNT327 combined with chemotherapy etoposidecarboplatin compared to atezolizumab combined with the same chemotherapy for participants with previously untreated extensive-stage small-cell lung cancer. This Phase III, multisite, randomized, double-blinded study aims to compare these treatments to better understand options for first-line ES-SCLC therapy. The study has two stages involving different treatment arms. Stage 1 includes two pumitamig doses combined with chemotherapy and one control arm with atezolizumab plus chemotherapy. Stage 2 has one pumitamig dose treatment arm and a control arm with atezolizumab plus chemotherapy. Participants receive intravenous infusions of study drugs, with the option to switch from carboplatin to cisplatin if needed. Each stage has a screening period up to 21 days, followed by induction and maintenance treatment until disease progression, intolerable side effects, withdrawal, study end, or up to 2 years, then a safety and survival follow-up period. Participants undergo screening to confirm eligibility, then receive treatments according to randomization. Assessments include survival, progression-free survival, response rates, duration of response, and quality of life measured through questionnaires. Safety monitoring tracks adverse events and treatment delays or discontinuations. Follow-up includes safety visits and survival tracking, with total participation lasting up to approximately 46 months from start. The study is designed to monitor long-term outcomes and tolerability of these combinations in ES-SCLC treatment.